Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit
April 05, 2024 10:00 ET
|
Medicovestor Inc
Medicovestor named finalist for JP Morgan Asset Management: Life Sciences Innovation Summit, showcasing pioneering ADC platforms on May 14th – 15th, 2024.
HNL Lab Medicine Unveils Lifesaving Cellular Therapy Laboratory
April 01, 2024 14:01 ET
|
Health Network Laboratories (HNL Lab Medicine)
HNL Lab Medicine partners with LVHN to open cellular therapy laboratory, first in Lehigh Valley; capable of apheresis collections and stem cell processing
TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters
March 25, 2024 08:02 ET
|
TeleDaas PLLC
TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
March 19, 2024 08:00 ET
|
Ludwig Enterprises, Inc.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
March 06, 2024 08:00 ET
|
Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
February 06, 2024 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
February 05, 2024 09:00 ET
|
ProLynx Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors...
Radiotherapy Market to grow by USD 12.2 billion by 2033, Globally at 5.9% CAGR | Market.us
January 29, 2024 07:10 ET
|
Market.Us
New York, Jan. 29, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the global radiotherapy market size is forecasted to exceed USD 12.2 billion by 2033, with a promising CAGR of 5.9% from 2024 to...
Photodynamic Therapy Market Set to Hit USD 5.53 Billion by 2033 | Boosting Opportunities for Medical Innovations
January 18, 2024 06:51 ET
|
Market.Us
New York, Jan. 18, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Photodynamic therapy market size is projected to surpass around USD 5.53 Billion by 2033, and it is poised to reach a...
Multi-Cancer Early Detection Market Size to Reach US$2.5 Bn by 2030, Fairfield Market Research Indicates Europe’s Leadership
December 13, 2023 08:56 ET
|
Fairfield Consultancy Services OPC Pvt Ltd
London, Dec. 13, 2023 (GLOBE NEWSWIRE) -- The global multi-cancer early detection market, presently valued at approximately US$0.89 Bn, is projected to witness an impressive CAGR of 16.3% through...